Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

The key is to balance offense and defense. by Leandro DalleMule and Thomas H. Davenport More than ever, the ability to manage torrents of data is critical to a company’s success. But even with the ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on knowledge of ...

Australia's NEXTDC inks MoU with OpenAI to develop AI infrastructure in Sydney, shares jump NEXTDC Ltd said on Friday it inked a memorandum of understanding with ChatGPT maker OpenAI to collaborate on ...